Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis
Amount Raised
$11 Million
Round Type
Funding Round
LebanonManufacturingHealthcareHealth CareDescription
Bryn Pharma, LLC ("Bryn" or the "Company"), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that it has raised an additional $11 million in financing to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, its bi-dose epinephrine nasal spray. The financing was an extension of the financing transaction completed by the Company in October 2019 and brings the total proceeds from the transaction to $26 million. This was the fourth financing series completed by the Company. Participants included existing and new investors comprised of investment funds, family offices and private investors.
Who to call at Bryn Pharma, and when
A new round usually means Bryn Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Bryn Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bryn Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bryn Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bryn Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Bryn Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.